Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T15:56:42.627Z.
Calculation as of: 2026-10-06T15:56:42.627Z.
Quote observation: 2026-10-06T15:55:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 767633254d5919bd59cda52a5696942c7bb29bc9076435c5b91744fa0c767718
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$43.56M
EBITDA Yield
N/A
TTM Avg
14.45%
3Y Avg
11.70%
5Y Avg
11.70%
Market Cap
$48.27M
EBITDA Yield
N/A
TTM Avg
0.84%
3Y Avg
0.84%
5Y Avg
0.84%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Werewolf Therapeutics, Inc. (HOWL) | $45.21M | N/A | N/A | N/A | N/A |
| CVRx, Inc. (CVRX)vs › | $44.58M | N/A | N/A | N/A | N/A |
| DarioHealth Corp. (DRIO)vs › | $44.35M | N/A | 8.08% | 7.24% | 6.66% |
| Nano-X Imaging Ltd. (NNOX)vs › | $44.03M | N/A | N/A | N/A | N/A |
| BioStem Technologies, Inc. (BSEM)vs › | $43.56M | N/A | 14.45% | 11.70% | 11.70% |
| Precision Optics Corporation, Inc. (POCI)vs › | $48.27M | N/A | 0.84% | 0.84% | 0.84% |
| Precipio, Inc. (PRPO)vs › | $41.92M | N/A | 0.46% | 0.46% | 0.46% |
| Lite Strategy, Inc. (LITS)vs › | $48.68M | N/A | N/A | N/A | N/A |
| Filana Therapeutics, Inc. (FLNA)vs › | $41.26M | N/A | N/A | N/A | N/A |
| Apollomics, Inc. (APLM)vs › | $49.85M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
